Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -58.29% is 68% above its 4-year average of -185.00%, near the high end of its 4-year range (-361.83%–-23.82%).
14.51% above its 12-month average of -68.18%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -83.65%.
EBITDA MARGIN
-58.29%
EBITDA MARGIN AVG TTM
-68.18%
EBITDA MARGIN AVG 3Y
-116.60%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+14.51%
CURRENT VS 3Y AVG
+50.01%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TriSalus Life Sciences, Inc.
Market Cap
$270.31M
EBITDA Margin
-58.29%
TTM Avg
-68.18%
3Y Avg
-116.60%
5Y Avg
N/A
Market Cap
$269.97M
EBITDA Margin
-2882.46%
TTM Avg
-2207.86%
3Y Avg
-1135.55%
5Y Avg
-791.10%
Market Cap
$269.95M
EBITDA Margin
-64.44%
TTM Avg
-40.40%
3Y Avg
-20.73%
5Y Avg
-9.01%
Market Cap
$271.00M
EBITDA Margin
-2082.59%
TTM Avg
-1743.06%
3Y Avg
-1015.79%
5Y Avg
-806.48%
Market Cap
$267.20M
EBITDA Margin
-7643.91%
TTM Avg
-11162.31%
3Y Avg
-5581.16%
5Y Avg
-3720.77%
Market Cap
$273.53M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.98M
EBITDA Margin
-20.52%
TTM Avg
-21.55%
3Y Avg
-22.69%
5Y Avg
-17.32%
Market Cap
$264.16M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $270.31M | -58.29% | -68.18% | -116.60% | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.97M | -2882.46% | -2207.86% | -1135.55% | -791.10% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $269.95M | -64.44% | -40.40% | -20.73% | -9.01% |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.89M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $267.20M | -7643.91% | -11162.31% | -5581.16% | -3720.77% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $273.53M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $265.98M | -20.52% | -21.55% | -22.69% | -17.32% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.83M | -9077.06% | -6066.11% | -4339.03% | -4339.03% |
Gross Margin
85.8%
EBITDA Margin
-58.3%
Operating Margin
-59.7%
Net Margin
-62.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -83.65% |
| 2026-03-31 | -93.00% |
| 2025-12-31 | -23.82% |
| 2025-09-30 | -76.53% |
| 2025-06-30 | -63.92% |
| 2025-03-31 | -78.07% |
| 2024-12-31 | -89.42% |
| 2024-09-30 | -116.61% |
| 2024-06-30 | -108.19% |
| 2024-03-31 | -178.05% |
| 2023-12-31 | -243.24% |
| 2023-09-30 | -355.48% |
| 2023-06-30 | -244.67% |
| 2023-03-31 | -333.01% |
| 2022-12-31 | -361.83% |
| 2022-09-30 | -202.40% |
| 2022-06-30 | -300.87% |
| 2022-03-31 | -321.35% |
| 2021-12-31 | -240.84% |
